A randomized controlled trial on focal therapy for localized prostate carcinoma: Hemiablation versus complete ablation with irreversible electroporation

Journal of Endourology

Volumn 27, Issue 3, 2013, Pages 261-264

  van den Bos, W ^a   Muller, B G ^a   de la Rosette, J J C M H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ARTICLE; COMPARATIVE STUDY; ELECTROPORATION; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ABLATION TECHNIQUES; ELECTROPORATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883886079     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2013.1568     Document Type: Article

References (23)

1. Eggener S, Salomon G, Scardino PT, et al. Focal therapy for prostate cancer: Possibilities and limitations. Eur Urol 2010;58:57-64.
2. de la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer—report from a consensus panel. J Endourol 2010;24:775-780.
3. Bott SR, Henderson A, McLarty E, Langley SE. A brachytherapy template approach to standardize saturation prostatic biopsy. BJU Int 2004;93:629-630.
4. Madersbacher S, Pedevilla M, Vingers L, et al. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995;55:3346-3351.
5. El Fegoun AB, Barret E, Prapotnich D, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 2011;37:213-222.
6. Truesdale MD, Cheetham PJ, Hruby GW, et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J 2010;16:544-549.
7. Bahn DK, Lee F, Badalament R, et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60(suppl 1):3-11.
8. Onik G, Vaughan D, Lotenfoe R, et al. “Male lumpectomy”: Focal therapy for prostate cancer using cryoablation. Urology 2007;70(suppl 6):16-21.
9. Assessing the potential for reduced toxicity using focal brachytherapy in early stage, low volume prostate cancer. http://clinicaltrials.gov/show/NCT01354951. Accessed on February 8, 2013.
10. Cosset JM, Wakil G, Pierrat N, et al. Focal brachytherapy for prostate cancer: A pilot study. Radiother Oncol 2011;99 (suppl 1):S283.
11. Langley S, Ahmed HU, Al-Qaisieh B, et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012;109(suppl 1):7-16.
12. Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer—a review of current status and future promise. Nat Clin Pract Urol 2009;6:18-30.
13. Azzouzi A-R, Emberton M. Results of Tookad soluble vascular targeted photodynamic therapy (VTP) for low risk localized prostate cancer. AUA 2011: Washington, DC; 2011.
14. Al-Sakere B, Andre F, Bernat C, et al. Tumor ablation with irreversible electroporation. PLoS One 2007;2:e1135.
15. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005;33:223-231.
16. Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: A new challenge in “out of operating theater” anesthesia. Anesth Analg 2010;110:1305-1309.
17. Altunc S. Subnanosecond pulsed-power generated electric fields for cancer treatment. IEEE Nucl Plasma Sci Soc News 34 (2009) 2012.
18. Garner AL, Chen G, Chen N, et al. Ultrashort electric pulse induced changes in cellular dielectric properties. Biochem Biophys Res Commun 2007;362:139-144.
19. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat 2005;4:699-705.
20. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: A new ablation modality—clinical implications. Technol Cancer Res Treat 2007;6:37-48.
21. Joshi RP, Schoenbach KH. Bioelectric effects of intense ultrashort pulses. Crit Rev Biomed Eng 2010;38:255-304.
22. Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation ablation: Is all the damage nonthermal? Radiology 2013;266:462-470.
23. D'Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163-2172.